পৃষ্ঠা 1 থেকে 30 ফলাফল
FIELD OF THE INVENTION
The present invention relates to novel compounds, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors of
SEQUENCE LISTING
The sequence listing submitted via EFS, in compliance with 37 CFR .sctn.1.52(e)(5), is incorporated herein by reference. The sequence listing text file submitted via EFS contains the file "SequenceListing6USCNT3," created on Feb. 17, 2010, which is 341,760 bytes in size.
FIELD OF
TECHNICAL FIELD
This invention relates to inhibitors of protein tyrosine phosphatase 1B (PTP1B) and other protein tyrosine phosphatases (PTPases).
BACKGROUND
Protein tyrosine phosphatases (PTPases) are a large family of diverse molecules that can play an important role in modulating a wide variety
FIELD OF THE INVENTION
The present invention relates to novel thienopyridines, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors
FIELD OF THE INVENTION
The present invention relates to novel compounds, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors of
FIELD OF THE INVENTION
The present invention relates to novel compounds, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors of
FIELD OF THE INVENTION
The present invention relates to novel compounds, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors of
FIELD OF THE INVENTION
This invention relates to the field of protein tyrosine phosphatase inhibition.
BACKGROUND OF THE INVENTION
This invention relates to a novel class of phosphonic acid derivatives that are inhibitors of PTP-1B.
Reversible protein tyrosine phosphorylation, coordinated by the
FIELD OF THE INVENTION
This invention relates to the field of protein tyrosine phosphatase inhibition.
BACKGROUND OF THE INVENTION
This invention relates to a novel class of phosphonic acid derivatives that are inhibitors of PTP-1B.
Reversible protein tyrosine phosphorylation, coordinated by the
FIELD OF THE INVENTION
The present invention relates to novel compounds, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors of
FIELD OF THE INVENTION
The present invention relates to antibodies that specifically bind to intracellular domains of two or more kinds of protein tyrosine phosphatases (hereinafter referred to as PTPs) and to methods for generating the same. More particularly, the present invention relates to
This application is the National Stage of Application No. PCT/EP2006/046543, filed on Dec. 6, 2006, which claims benefit under 35 U.S.C. .sctn.119(a-d) of U.S. Provisional Application No. 60/748,491, filed Dec. 8, 2005, the contents of which are incorporated herein by reference in their
FIELD OF THE INVENTION
The present invention is related to the use of oxindole hydrazide derivatives of formula (I) for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin
FIELD OF THE INVENTION
The present invention is related to substituted methylene amide derivatives of formula (I), in particular for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates generally to insulin resistance and specifically to a method for identifying compositions which inhibit binding of protein tyrosine phosphatase 1B (PTP1B) to the .beta.-subunit of the activated insulin receptor.
2.